4.4 Editorial Material

Breathing New Life Into Hypoxia-Targeted Therapies for Non-Small Cell Lung Cancer

Related references

Note: Only part of the references are listed.
Review Oncology

Targeting Hypoxia to Improve Non-Small Cell Lung Cancer Outcome

Ahmed Salem et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)

Review Oncology

Targeting Hypoxia to Improve Non-Small Cell Lung Cancer Outcome

Ahmed Salem et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)

Article Pharmacology & Pharmacy

A2A adenosine receptor antagonists to weaken the hypoxia-HIF-1α driven immunosuppression and improve immunotherapies of cancer

Stephen M. Hatfield et al.

CURRENT OPINION IN PHARMACOLOGY (2016)

Article Oncology

Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?

Michael B. Bernstein et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2016)

Article Medicine, General & Internal

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

Martin Reck et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Article Medicine, General & Internal

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

Julie Brahmer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Article Medicine, General & Internal

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

H. Borghaei et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Article Oncology

Lung Adjuvant Cisplatin Evaluation: A pooled analysis by the LACE collaborative group

Jean-Pierre Pignon et al.

JOURNAL OF CLINICAL ONCOLOGY (2008)